Swiss Re’s Gilead Sciences GILD Stock Holding History

Swiss Re’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$35K	Hold	251	–	–	0.21%	61
2025 Q4	$30.8K	Buy	+251	New	+$30.5K	﹤0.01%	71

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Swiss Re's GILD Position: Q1 2026 in Review

Swiss Re held its Gilead Sciences (GILD) position steady in Q1 2026 at 251 shares worth $35K. The position accounts for 0.21% of the portfolio, ranked #61.

Swiss Re first reported a position in GILD in Q4 2025 and has held it in 2 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Swiss Re held 251 shares of Gilead Sciences worth $35K as of Q1 2026.
Swiss Re left its Gilead Sciences share count unchanged in Q1 2026.
Gilead Sciences made up 0.21% of Swiss Re's portfolio in Q1 2026, its #61 holding.
Swiss Re first reported a position in Gilead Sciences in Q4 2025 and has held it in 2 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Swiss Re's 13F filing for Q1 2026, filed 12 May 2026.